×
About 5,168 results

ALLMedicine™ Hidradenitis Suppurativa Center

Research & Reviews  1,632 results

A practical guide to hidradenitis suppurativa.
https://doi.org/10.12788/jfp.0525
The Journal of Family Practice; Marti-Amarista C, Rali M

Feb 4th, 2023 - Early diagnosis and treatment of hidradenitis suppurativa is key to avoiding severe disease and minimizing its negative psychological impact.

Dapsone therapy for hidradenitis suppurativa: a retrospective review of characteristics...
https://doi.org/10.1093/bjd/ljac120
The British Journal of Dermatology; Steyn M, Ayis S et. al.

Feb 4th, 2023 - Dapsone therapy for hidradenitis suppurativa: a retrospective review of characteristics and treatment outcomes in a cohort of 122 patients in a tertiary dermatology setting.|2023|Steyn M,Ayis S,O'Connor J,Lakhan MK,Ferguson F,|

A Study to Evaluate the Efficacy and Safety of Bimekizumab in Study Participants With Moderate to Severe Hidradenitis Suppurativa
https://clinicaltrials.gov/ct2/show/NCT04242446

Feb 3rd, 2023 - The purpose of the study is to evaluate the efficacy and safety of bimekizumab in study participants with moderate to severe hidradenitis suppurativa (HS)

A Study to Test the Long-term Treatment of Bimekizumab in Study Participants With Moderate to Severe Hidradenitis Suppurativa
https://clinicaltrials.gov/ct2/show/NCT04901195

Feb 3rd, 2023 - The purpose of the study is to evaluate the safety of long-term therapy of bimekizumab in study participants with moderate to severe hidradenitis suppurativa (HS)

Successful treatment with anakinra in generalized spiculated porokeratosis and severe h...
https://doi.org/10.1093/ced/llac023
Clinical and Experimental Dermatology; Oktem A, Rasulova G et. al.

Feb 3rd, 2023 - Successful treatment with anakinra in generalized spiculated porokeratosis and severe hidradenitis suppurativa in a patient with MVK and MEFV mutations.|2023|Oktem A,Rasulova G,Cavdarli B,Bostanci S,Heper A,|

see more →

Guidelines  1 results

Updates on treatment guidelines for psoriasis, atopic dermatitis (eczema), hidradenitis...
https://www.ncbi.nlm.nih.gov/pubmed/33147660
Dermatology Online Journal; Yim RM, Singh I et. al.

Nov 5th, 2020 - Owing to the evolving COVID-19 pandemic and emerging data regarding immunosuppressant therapies for inflammatory cutaneous diseases, dermatologists are being encouraged to reevaluate their patients' treatment regimens to minimize any potential ris...

see more →

Drugs  1 results see all →

Clinicaltrials.gov  147 results

A Study to Test the Long-term Treatment of Bimekizumab in Study Participants With Moderate to Severe Hidradenitis Suppurativa
https://clinicaltrials.gov/ct2/show/NCT04901195

Feb 3rd, 2023 - The purpose of the study is to evaluate the safety of long-term therapy of bimekizumab in study participants with moderate to severe hidradenitis suppurativa (HS)

A Study to Evaluate the Efficacy and Safety of Bimekizumab in Study Participants With Moderate to Severe Hidradenitis Suppurativa
https://clinicaltrials.gov/ct2/show/NCT04242446

Feb 3rd, 2023 - The purpose of the study is to evaluate the efficacy and safety of bimekizumab in study participants with moderate to severe hidradenitis suppurativa (HS)

Hidradenitis - an Analysis of Genetic Traits and Linkages in Families
https://clinicaltrials.gov/ct2/show/NCT05710393

Feb 2nd, 2023 - Hidradenitis suppurativa (HS) is a chronic, debilitating skin disease characterized by multiple abscesses located predominantly in areas such as armpit, genital, pelvic, and perineum. It is considered an orphan disease of unknown origin and no exi...

Hidradenitis Suppurativa Wound Care
https://clinicaltrials.gov/ct2/show/NCT04354012

Feb 2nd, 2023 - Hidradenitis suppurativa (HS) is a chronic and debilitating inflammatory disease most frequently affecting the axilla, groin, and inframammary regions. Symptoms include nodules, abscesses, sinus tract formation, malodorous drainage, and scarring. ...

Evaluation of Sonelokimab for the Treatment of Patients With Active Moderate to Severe Hidradenitis Suppurativa
https://clinicaltrials.gov/ct2/show/NCT05322473

Feb 2nd, 2023 - This is a study to demonstrate the clinical efficacy and safety of the nanobody® sonelokimab administered subcutaneously (sc) compared with placebo in the treatment of adult participants with moderate to severe hidradenitis suppurativa.

see more →

News  271 results

Scalp ridges
https://www.mdedge.com/familymedicine/article/260934/dermatology/scalp-ridges
MDedge Family Medicine;

Jan 31st, 2023 - The gyrate or cerebriform pattern of inflammatory, often pus-filled, subcutaneous tracts of the scalp pointed to a diagnosis of dissecting cellulitis. This patient did not have the fluctuant tracts frequently seen in more active disease but did ha.

Phase III Trials Back Bimekizumab for Spondyloarthritis
https://www.medpagetoday.com/rheumatology/arthritis/102660

Jan 17th, 2023 - Bimekizumab, an investigational biologic drug targeting interleukin (IL)-17A/F, appeared highly effective in patients with axial spondyloarthritis (axSpA), researchers said. With nearly 600 patients enrolled in two parallel phase III trials, 45% a...

A practical guide to hidradenitis suppurativa
https://www.mdedge.com/familymedicine/article/260048/dermatology/practical-guide-hidradenitis-suppurativa
MDedge Family Medicine; Cristina Marti-Amarista, MD, Mayur Rali, MD

Dec 12th, 2022 - Hidradenitis suppurativa (HS), also known as acne inversa or Verneuil disease, is a chronic, recurrent, inflammatory occlusive disease affecting the terminal follicular epithelium in apocrine gland–bearing skin areas. 1 HS manifests as painful nodu.

Consider quality of life, comorbidities in hidradenitis suppurativa
https://www.mdedge.com/dermatology/article/259896/medical-dermatology/consider-quality-life-comorbidities-hidradenitis
Heidi Splete

Dec 2nd, 2022 - LAS VEGAS – The delay in the diagnosis of hidradenitis suppurativa (HS) often ranges from 7 to 10 years, which results in increased morbidity and disease severity, and an extended impact on quality of life, Robert G. Micheletti, MD, said in a pres.

HS treated in EDs not followed up in derm clinics, study finds
https://www.mdedge.com/dermatology/article/259857/medical-dermatology/hs-treated-eds-not-followed-derm-clinics-study-finds
Lorraine L. Janeczko, MPH

Dec 1st, 2022 - Many patients with hidradenitis suppurativa (HS) return to emergency departments – not to dermatology clinics – for their ongoing care, according to a study of a large national administrative data set. “Patients with HS presenting to the ED for th.

see more →

Patient Education  15 results see all →